Skip to main content
Clinical Trials/CTRI/2024/02/063353
CTRI/2024/02/063353
Not yet recruiting
Phase 3

To compare the efficacy and adverse effects of oral tofacitinib and oral methylprednisolone mini-pulse and combination of both in treatment of alopecia areata: A Randomized Controlled Trial. - NI

Institute of Medical Sciences BH0 sites0 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Health Condition 1: L639- Alopecia areata, unspecified
Sponsor
Institute of Medical Sciences BH
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Institute of Medical Sciences BH

Eligibility Criteria

Inclusion Criteria

  • 1\. Clinically diagnosed cases of alopecia areata with severity of alopecia tool (SALT) score of 10 % or over.
  • 2\. Age: 18 to 65 years
  • 3\. Patients not taking systemic drug in last 1 month and topical treatment in last 15 days.
  • \- All participants who give consent for the study

Exclusion Criteria

  • 1\. Patients having history or active tuberculosis.
  • 2\. Patients with Pregnancy and lactating mother.
  • 3\. Patients with uncontrolled renal, hepatic,
  • hematological or heart disease.
  • 4\. Patients with diabetes mellitus and hypertension.

Outcomes

Primary Outcomes

Not specified

Similar Trials